Mitsubishi UFJ Finl Grの空売り状況は、投資家がMitsubishi UFJ Finl Grの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Mitsubishi UFJ Finl Gr (NYSE:MUFG) 株価情報, 空売り情報

Mitsubishi UFJ Finl Gr

Mitsubishi UFJ Financial Group is the largest bank in Japan in terms of market capitalization and assets, with an 8.0% share of all domestic loans as of March 2024. It is the largest non-Chinese bank group globally and has a balance sheet slightly larger than those of JPMorgan Chase and HSBC Holdings. MUFG's operations in Japan account for around half of profit, banking in Thailand and Indonesia for around 15%, and equity-method earnings from Morgan Stanley most of the rest.

Mitsubishi UFJ Financial Group, Inc. Common Stock

Mitsubishi UFJ Financial Group Inc

Scotiabank analyst Tanya Jakusconek maintains Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) with a Sector Perform and raises the price target from $165 to $169.

News

Price Target

Analyst Ratings

Scotiabank Maintains Sector Perform on Franco-Nevada, Raises Price Target to $169

Scotiabank analyst Nicholas Yulico maintains First Industrial Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FR#NYSE">FR</a>) with a Sector Perform and raises the price target from $50 to $51.

Scotiabank Maintains Sector Perform on First Industrial Realty, Raises Price Target to $51

Macro Economic Events

Politics

Global

Economics

Federal Reserve

General

Fed's Kugler Reportedly Says I Am One Of Those Who Believes There Could Be Some Permanency From Price Increases Related To Tariffs

Scotiabank analyst Phil Hardie maintains Fiera Cap (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FSZ#TSX">FSZ</a>) with a Sector Perform and lowers the price target from C$7 to C$6.5.

TSX:FSZ

Scotiabank Maintains Sector Perform on Fiera Cap, Lowers Price Target to C$6.5

WIIM

NRXS

Neuraxis shares are trading higher after the company reported a year-over-year increase in Q1 sales results.

Scotiabank analyst Nicholas Yulico maintains Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) with a Sector Outperform and raises the price target from $149 to $166.

Scotiabank Maintains Sector Outperform on Extra Space Storage, Raises Price Target to $166

Automatic Data Processing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADP#NASDAQ">ADP</a>) has outperformed the market over the past 5 years by 2.7% on an annualized basis producing an average annual return of 17.84%. Currently, Automatic Data Processing has a market capitalization of $124.67 billion. 
Buying $100 In ADP: If an investor had bought $100 of ADP stock 5 years ago, it would be worth $227.05 today based on a price of $306.40 for ADP at the time of writing.
<h3>Automatic Data Processing's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747062990_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today

Reuters Reports Fed's Kugler Reportedly Says If Tariffs Long Lasting, The One Issue I Would Be Looking To Is How Supply Chains Get Rearranged In The Rest Of The World; U.S./China Tariff Reduction Obviously An Improvement As Far As Trade Between Countries Go, Still Pretty High; Still Expect Increase In Prices And Slowdown In Economy Though Not To Same Rate As Before; Extent Of Uncertainty May Have Gone Down A Bit, Extent Of Supply Shock

IVVD

Invivyd shares are trading higher after the company announced it has initiated a discovery program for a measles monoclonal antibody.

Scotiabank analyst Nicholas Yulico maintains Essex Property Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) with a Sector Outperform and raises the price target from $329 to $344.

Scotiabank Maintains Sector Outperform on Essex Property Trust, Raises Price Target to $344

BLDE

Blade Air Mobility shares are trading higher after the company reported better-than-expected Q1 financial results.

Mizuho analyst Siti Panigrahi maintains BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) with a Neutral and lowers the price target from $53 to $50.

BILL

Mizuho Maintains Neutral on BILL Holdings, Lowers Price Target to $50

Legendary investor Warren Buffett may have shocked the investing world recently with an announcement that he will be stepping down as the longtime CEO of Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) at the<a href="https://www.benzinga.com/25/05/45184410/warren-buffett-to-step-down-as-berkshire-hathaway-ceo-by-end-of-year-asks-board-to-confirm-greg-abel-as-successor"> end of 2025.</a>
With the latest news, here's a look back at some of the largest acquisitions made by Buffett during his time leading Berkshire Hataway.
What Happened: Berkshire Hathaway has produced market-beating returns for many years, with Buffett's leadership helping the company <a href="https://www.benzinga.com/general/education/25/01/42832123/warren-buffett-beats-sp-500-in-2024-how-oracle-of-omahas-returns-compare-over-past-20-years">outperform the S&amp;P 500</a> through a strategy of acquisitions and stock holdings.
Benzinga previously shared a look at the<a href="https://www.benzinga.com/general/education/25/05/45208955/warren-buffetts-giant-berkshire-portfolio-top-10-includes-banks-oil-and-apple"> top 10 stock holdings</a> in the Berkshire Hathaway portfolio. Along with the public stocks held, the diversified conglomerate owns companies in sectors like consumer products, energy, utilities, industrial, railroads, insurance and more.
Here are 10 of the largest acquisitions made by Berkshire Hathaway during Buffett's leadership, according to a report from Business Insider and a chart from Freedom Capital Markets Chief Global Strategist Jay Woods' weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
<ol class="wp-block-list">
<li>Precision Castparts Corp: $37.2 billion, 2016, aerospace/industrial</li>
<li>Burlington Northern Santa Fe: $34 billion, 2010, railroads</li>
<li>Heinz/Kraft Heinz: $28 billion, 2013, food/consumer goods</li>
<li>General Reinsurance: $22 billion, 1998, reinsurance</li>
<li>Pilot Flying J: $13.6 billion, 2017 to 2024, truck stops</li>
<li>Alleghany Corporation: $11.6 billion, 2022, insurance</li>
<li>Dominion Energy: $10.0 billion, 2020, natural gas/energy</li>
<li>Lubrizol Corporation: $9.7 billion, 2011, chemicals</li>
<li>PacificCorp: $9.4 billion, 2005, utilities</li>
<li>NV Energy: $5.6 billion, 2013, utilities</li>
</ol>
The Heinz acquisition is notable. Buffett partnered with 3G Capital to acquire the company and later helped facilitate a merger with Kraft Foods with an additional equity commitment. Kraft Heinz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KHC#NASDAQ">KHC</a>) is now publicly traded, with Berkshire Hathaway owning around 27.5% of the company, with a stake valued at around $9.1 billion.
Pilot Flying J was one of several companies where Buffett took a small stake and eventually bought the company outright. The value is the total spent by Berkshire Hathaway to acquire the company in several equity stakes.
Read Also: <a href="https://www.benzinga.com/general/education/25/05/45211516/warren-buffetts-ceo-challenge-which-of-your-competitors-stocks-would-you-buy">Warren Buffett&#8217;s CEO Challenge: &#8216;Which Of Your Competitors&#8217; Stocks Would You Buy?&#8217;</a>
Why It's Important: The above acquisitions show that despite Berkshire Hathaway being a $1.11 trillion company today, the conglomerate has made many small bets when it comes to acquisitions.
Only three of the company's acquisitions were $25 billion or larger deals and only seven of the deals were valued at $10 billion or more.
Buffett's largest acquisitions reveal a clear preference for sectors like utilities, railroads, insurance, and energy — all of which remain core pillars of Berkshire Hathaway's portfolio today.
Berkshire Hathaway currently has a cash balance of more than $300 billion, which will likely remain on the balance sheet <a href="https://www.benzinga.com/25/05/45237968/5-facts-you-might-not-know-about-warren-buffett-successor-greg-abel">when new CEO </a>Greg Abel takes over the company from the legendary investor.
Berkshire Hathaway investors will be closely watching to see if Abel uses the cash for new acquisitions or stock investments in 2026.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45232692/if-you-invested-1000-in-berkshire-hathaway-stock-when-warren-buffett-did-heres-how-much-youd-have-now">If You Invested $1,000 In Berkshire Hathaway Stock When Warren Buffett Did, Here&#8217;s How Much You&#8217;d Have Now</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Insurance

Warren Buffett's Big Bets: 10 Of Berkshire's Largest Deals Reveal Diversification Strategy

Mizuho analyst Siti Panigrahi maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Neutral and raises the price target from $25 to $27.

Mizuho Maintains Neutral on RingCentral, Raises Price Target to $27

CytomX Therapeutics, Inc.&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) share price was up 94.46% at last check on Monday.
The stock surged after the company reported interim Phase 1 data for its EpCAM PROBODY ADC candidate, CX-2051, in advanced, late-line <a href="https://www.benzinga.com/general/biotech" target="_blank" rel="noreferrer noopener">colorectal cancer (CRC)</a>.
As of April 7, 25 advanced metastatic CRC patients were treated with CX-2051 across <a href="https://www.benzinga.com/pressreleases/25/05/g45342877/cytomx-announces-positive-interim-data-from-phase-1-dose-escalation-study-of-epcam-antibody-drug-c" target="_blank" rel="noreferrer noopener">dose levels 1 through 5</a>.
CX-2051 was administered on a once every three-week schedule (Q3W).
<ul class="wp-block-list">
<li>The 2.4 mg/kg and 4.8 mg/kg doses were single-patient dose escalation cohorts that were not anticipated to be therapeutically active.</li>
<li>At the 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg doses, 23 patients were treated, 18 of whom were efficacy evaluable, having had at least one post-baseline tumor assessment as of the data cutoff.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44708568/exclusive-anixa-biosciences-receives-key-us-patent-nod-for-breast-cancer-vaccine-patent" rel="noreferrer noopener">EXCLUSIVE: Anixa Biosciences Receives Key US Patent Nod For Breast Cancer Vaccine Patent</a>
28% of patients (5/18) achieved a confirmed partial overall response rate (ORR).
<ul class="wp-block-list">
<li>At the 10 mg/kg dose, 3 of 7 evaluable patients (43%) achieved confirmed partial responses.</li>
<li>The Disease Control Rate&nbsp;was 94% across the three dose groups (17/18).&nbsp;&nbsp;</li>
</ul>
Median progression-free survival was 5.8 months as of the data cutoff.
<ul class="wp-block-list">
<li>10 of 18 patients remained on study treatment as of the cutoff data.&nbsp;&nbsp;</li>
</ul>
CX-2051 was generally well-tolerated with manageable adverse events, with no observed dose-limiting toxicities.
Most treatment-related adverse events (TRAEs) were Grade 1 (mild) or Grade 2 (moderate) in severity.&nbsp;&nbsp;
The company has initiated dose expansions at 7.2 mg/kg, 8.6 mg/kg, and 10 mg/kg Q3W levels.
<ul class="wp-block-list">
<li>A total of 20 patients are expected to be enrolled at each dose level to inform the selection of the recommended phase 2 dose.</li>
</ul>
The company expects to report additional Phase 1 data from CX-2051 monotherapy for advanced late-line CRC by the first quarter of 2026, and plans to initiate a Phase 2 study in the first half of 2026.
CytomX also plans to initiate CX-2051 combination studies in earlier lines of CRC in 2026.
The company plans to evaluate CX-2051 in non-CRC, EpCAM-expressing tumor indications for potential Phase 1b study initiation in 2026.
On Monday, &nbsp;CytomX Therapeutics priced its underwritten offering of approximately 76.92 million shares at $1.30 per share, raising $100 million <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45343457/cytomx-therapeutics-announces-pricing-of-100-million-underwritten-offering-of-common-stock" rel="noreferrer noopener">in gross proceeds</a>.
The company said that focused clinical development priorities and cost reductions implemented in the first quarter of 2025 extended the company&#8217;s cash runway into the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45342879/cytomx-therapeutics-announces-first-quarter-2025-financial-results-and-provides-business-update" rel="noreferrer noopener">second quarter of 2026</a>.
CytomX ended the quarter with $79.9 million in cash, cash equivalents, and investments.
Price Action: CTMX stock is up 86.5% at $1.73 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45347011/pan-american-acquires-mag-for-2-1-billion" target="_blank" rel="noreferrer noopener">Pan American Acquires MAG For $2.1 Billion</a></li>
</ul>
Image: Shutterstock

Biotech

Health Care

Financing

Offerings

Movers

CTMX

Nano-Cap CytomX Therapeutics Stock Surges On Heels Of Cancer Data Report

Mizuho analyst Mara Goldstein maintains Iovance Biotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) with a Outperform and lowers the price target from $30 to $10.

IOVA

Mizuho Maintains Outperform on Iovance Biotherapeutics, Lowers Price Target to $10

Scotiabank analyst Greg McGinniss maintains Essential Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Sector Perform and raises the price target from $32 to $33.

EPRT

Scotiabank Maintains Sector Perform on Essential Properties, Raises Price Target to $33

StoneX Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNEX#NASDAQ">SNEX</a>); today announced that its&nbsp;wholly owned subsidiary, StoneX Financial Europe GmbH, has entered into a definitive agreement to&nbsp;acquire Plantureux et Associés ("Plantureux"), a Paris-based brokerage firm specializing in&nbsp;agricultural commodities across both the physical and derivatives markets. &nbsp;The acquisition will&nbsp;provide StoneX with a strategic foothold in the French agricultural commodities market – Europe's&nbsp;leading grain producing region.&nbsp;&nbsp;
Completion of the acquisition is subject to regulatory approval and customary closing conditions. &nbsp;
This acquisition follows a series of strategic investments by StoneX Group in Europe. Earlier this year,&nbsp;StoneX Group expanded its fixed income capabilities in Europe through the successful acquisition of&nbsp;Octo Finances SA. &nbsp;&nbsp; &nbsp;

SNEX

StoneX Group's Subsidiary, StoneX Financial Europe, Agrees To Acquire Plantureux et Associés; Terms Not Disclosed

Scotiabank analyst Nicholas Yulico maintains Equity Residential (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQR#NYSE">EQR</a>) with a Sector Perform and raises the price target from $79 to $82.

Scotiabank Maintains Sector Perform on Equity Residential, Raises Price Target to $82

<a href="https://www.seroundtable.com/google-search-discussions-beta-feature-39393.html">https://www.seroundtable.com/google-search-discussions-beta-feature-39393.html</a>
Google has a new beta feature to encourage searchers to add comments and have discussions around a specific topic. It is called "Discussions" and has a beta label on it. You can add your own thoughts/comments to the topic and those comments can appear across a number of Google properties and services.
It makes you wonder if Google is potentially looking for ways to replace all those Reddit discussions with their own?
This was spotted by Nicholas McDonough who posted a number of screenshots on <a href="https://x.com/Callmenicholi/status/1921365910012436671">X</a> but I can replicate it, here are some of the screenshots.

GOOG

GOOGL

RDDT

'Google Search Discussions Beta May One Day Replace Reddit Results' - Search Engine Roundtable

Press Releases

MUFG continues build-out in the middle market space

Mitsubishi UFJ Financial Group, Inc. Announces Filing of Annual Report on Form 20-F for the Year Ended March 31, 2024

Fintech

MUFG and DWS Group Launch Private Financing Strategic Venture for Project and Infrastructure Asset Investments

MUFG Announces Multi-Year Partnership with LPGA Star Yuka Saso

First Sentier Investors appoints Ashley Conn as Chief Financial and Strategy Officer

MUFG announces new Head of CLO

MBFJF

MUFG

TYO:8306

Bank of America

Banco Bradesco Sa American Depositary Shares

Bank Bradesco

Banco Bradesco Sa American Depositary Shares (each representing one Common Share)

Banco Bilbao Vizcaya Argentaria S.A. Common Stock

BBVA

Barclays

Banco Santander Brasil SA American Depositary Shares, each representing one unit

Banco Santander

Citigroup

First Citizens BancShares, Inc. - Class A Common Stock

First Citizens BancShares

Fifth Third Bancorp

HDFC Bank

HSBC Holdings

ICICI Bank

ING Groep

Itau Unibanco Banco Holding SA American Depositary Shares (Each repstg 500 Preferred shares)

Itau Unibanco Holding

JPMorgan Chase

KB Financial Group

Lloyds Banking Group Plc American Depositary Shares

Lloyds Banking Group

Mizuho Financial Group, Inc. Sponosred ADR (Japan)

Mizuho Financial Gr

Nu Holdings

NatWest Group plc American Depositary Shares, (each representing two (2) Ordinary Shares)

NatWest Group

PNC Financial Services Group, Inc. (The) Common Stock

PNC Financial Services Gr

Banco Santander, S.A. Sponsored ADR (Spain)

Sumitomo Mitsui Financial Group Inc Unsponsored American Depositary Shares (Japan)

Comments

Mitsubishi UFJ Finl Gr

空売り

Mitsubishi UFJ Finl Gr (NYSE:MUFG) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル